Several strategies have been investigated to improve the 4% survival advantage of adjuvant chemotherapy in early-stage non-small cell lung cancer (NSCLC). We aimed to evaluate in this investigator-initiated study the predictive utility of the mRNA expression levels of ERCC1 and TS as assessed in resected tumor.
International Tailored Chemotherapy Adjuvant (ITACA) Trial, a Phase III Multicenter Randomized Trial Comparing Adjuvant Pharmacogenomic-Driven Chemotherapy versus Standard Adjuvant Chemotherapy in completely Resected Stage II-IIIA Non-Small Cell Lung Cancer
Novello, S;Meyer, A;Colantonio, I;Schena, M;Morabito, A;Monica, V;Porcu, L;Scagliotti, G V
2022-01-01
Abstract
Several strategies have been investigated to improve the 4% survival advantage of adjuvant chemotherapy in early-stage non-small cell lung cancer (NSCLC). We aimed to evaluate in this investigator-initiated study the predictive utility of the mRNA expression levels of ERCC1 and TS as assessed in resected tumor.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
INTERN~2.PDF
Open Access dal 06/10/2022
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
8.02 MB
Formato
Adobe PDF
|
8.02 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
